Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone

The incidence of left ventricular hypertrophy (LVH) in primary aldosteronism (PA) is higher than in essential hypertension. LVH is an independent cardiovascular risk factor. Treatment of PA with mineralocorticoid receptor blockers (MRBs) improves LVH. Previous studies included relatively small group...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nephrology, dialysis, transplantation dialysis, transplantation, 2013-07, Vol.28 (7), p.1787-1793
Hauptverfasser:	Ori, Yaacov, Chagnac, Avry, Korzets, Asher, Zingerman, Boris, Herman-Edelstein, Michal, Bergman, Michael, Gafter, Uzi, Salman, Hertzel
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Blood Pressure Determination Echocardiography Essential Hypertension Female Follow-Up Studies Humans Hyperaldosteronism - complications Hyperaldosteronism - drug therapy Hyperaldosteronism - metabolism Hypertension - complications Hypertension - drug therapy Hypertrophy, Left Ventricular - drug therapy Hypertrophy, Left Ventricular - etiology Hypertrophy, Left Ventricular - metabolism Male Middle Aged Mineralocorticoid Receptor Antagonists - therapeutic use Prognosis Renin - metabolism Retrospective Studies Risk Factors Spironolactone - therapeutic use Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!